- About Us
- Advertise
- Contact Us
- CureToday.com
- CancerNetwork.com
- OncLive.com
- OncNursingNews.com
- Do Not Sell My Information
- Privacy
- Terms & Conditions
© 2022 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Biomarker-Driven Lung Cancer | Clinical
Examining Trends of Biomarker Testing With the MYLUNG Study in mNSCLC
June 23, 2022
During an interview with Targeted Oncology, Nicholas J. Robert, MD, further discussed the data of the MYLUNG study which he presented in a poster at the 2022 American Society of Clinical Oncology Annual Meeting.
Trial of New RET Inhibitor Aims to Overcome Resistance in NSCLC and MTC
June 15, 2022
Nathan Pennell, MD, PhD, discusses a first-in-human trial of a novel RET inhibitor for patients with non–small cell lung cancer and medullary thyroid cancer.
Improved PFS With Toripalimab Plus Chemotherapy in NSCLC Regardless of PD-L1 Status
June 13, 2022
Combination of toripalimab and chemotherapy in the frontline setting shows survival benefit in patients with advanced non–small cell lung cancer without EGFR or ALK mutations, regardless of PD-L1 status.
Adagrasib Penetrates CNS in Early Data of KRAS G12C+ NSCLC
June 07, 2022
In patients enrolled in the phase 1b portion of the KRYSTAL-1 trial who received adagrasib, the intracranial objective response rate was 32%.
Pembrolizumab Alone Shows Best Response in NSCLC With 90% or Higher PD-L1 Expression
June 07, 2022
Treatment with pembrolizumab monotherapy demonstrated the best response in patients with non–small cell lung cancer and a PD-L1 tumor proportion score of 90% or more, according to a correlative analysis conducted with 3-years of follow-up.
Adagrasib Displays Encouraging Responses, Disease Control in KRAS G12C+ NSCLC
June 03, 2022
Treatment with the KRAS G12C inhibitor adagrasib showed a promising objective response rate and disease control rate in patients with previously treated KRAS G12C–mutated non–small cell lung cancer.
Manageable Safety/Efficacy With Erlotinib/Binimetinib in EGFR+ or KRAS+ NSCLC
June 01, 2022
Andreas Saltos, MD, discussed treatment options for EGFR and KRAS-mutated NSCLC, and the investigational use of binimetinib to treat these tumors.
The Prevalence of MET Fusions in NSCLC
May 31, 2022
Yonina R. Murciano-Goroff, MD, MSc, DPhil, discussed the prevalence of MET fusions in patients with non-small cell lung cancer and the impact of identifying them when making treatment decisions.
Community Health Systems Test for Recommended Cancer Biomarkers More Often Than Independent Practices
May 26, 2022
In patients with advanced non-squamous non–small cell lung cancer treated within large community health systems in the United States , biomarker testing appeared to be significantly higher compared with independent community practices, research shows.
Trastuzumab Deruxtecan Shows Promising Efficacy for HER2-Mutated NSCLC
May 24, 2022
Lyudmila Bazhenova, MD, discusses targeted therapies for patients with HER2-mutated non–small cell lung cancer.